Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis

NCT ID: NCT01745133

Last Updated: 2016-11-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 63 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-01-31
• Study Completion Date: 2014-08-31

Brief Summary

The purpose of the study is to investigate if combined use of OLUX-E™ Foam and SORILUX Foam may help "maintain" the therapeutic benefit that is achieved with OLUX-E™ Foam in the treatment of moderate plaque psoriasis.

OLUX-E™ is a medication that contains a corticosteroid delivered in a foam formulation. SORILUX Foam is a foam formulation of calcipotriene. Both medications have been approved by the FDA for treating plaque psoriasis.

Detailed Description

This is a single-center, investigator-blind study. Approximately 60 qualified subjects will be enrolled into a 2 week treatment phase where they will receive 2 weeks of treatment with Olux E foam. After 2 weeks treatment, subjects with a PGA of 0 or 1 will be re-randomized into maintenance phase.

Subjects that achieve PGA scores of >2 will be discontinued from the study and will not be randomized. Subjects that achieve PGA scores of 0 or 1 will enter an 8 week maintenance phase where they will be randomized on a 1:1:1 basis to one of the following treatment groups:

• Vehicle foam (BID)
• Sorilux foam (BID)
• Sorilux foam (BID on weekdays) + Olux E foam (BID on weekends)

Subjects will then attend clinic visits at week 6. At week 10 study treatment will be stopped.

The maximum duration of the study is 10 weeks and consists of a Screening/Baseline Visit (Week -0), Re-randomization to maintenance phase visit (Week 2), treatment follow-up visits at Weeks 6, and end of treatment visit at weeks 10.

Conditions

Psoriasis

Keywords

Olux E foam; Sorilux foam

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

vehicle

clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks

Group Type: PLACEBO_COMPARATOR

vehicle foam

Intervention Type: DRUG

clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks

calcipotriene

clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks x

Group Type: ACTIVE_COMPARATOR

calcipotriene

Intervention Type: DRUG

clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks

calcipotriene + clobetasol propionate

clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays for 8 weeks + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks

Group Type: ACTIVE_COMPARATOR

calcipotriene + clobetasol propionate

Intervention Type: DRUG

clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks

Interventions

vehicle foam

clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks

Intervention Type: DRUG

calcipotriene

clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks

Intervention Type: DRUG

calcipotriene + clobetasol propionate

clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks

Intervention Type: DRUG

Other Intervention Names

Sorilux foam 0.005% foam; Sorilux foam + Olux E foam

Eligibility Criteria

Inclusion Criteria

• Outpatient, male or female subjects of any race, 18 years of age or higher. -Female subjects of childbearing potential must have a negative urine pregnancy test within 7 days prior to the first dose of study drug and practice a reliable method of contraception throughout the study [Exception: Female subjects of child bearing potential who are not sexually active are not required to practice a reliable method of contraception and may be enrolled at the Investigator's discretion provided they are counseled to remain sexually inactive for the duration of the study and understand the risks involved in getting pregnant during the study.]
• Moderate plaque type psoriasis eligible for topical therapies.
• A Bod Surface Area (BSA) of 3-10%.
• Physician Global Assessment(PGA) score of 3.
• Able to understand study requirements and sign Informed Consent/Health Insurance Portability and Accountability Act forms.

Exclusion Criteria

• Female subjects who are pregnant, breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control, or male subjects planning a pregnancy with their spouse or partner while in the study.
• History of hypocalcaemia or vitamin D toxicity.
• Serious skin condition (other than psoriasis) or uncontrolled medical condition (in the opinion of the investigator).
• Topical steroids, topical immunomodulators, topical vitamin D derivatives, tar, salicylic acid, anthralin or any other topical treatment for psoriasis within 2 weeks of baseline.
• Use of any biologics within 3 months of baseline.
• Use of other systemic psoriasis treatments (ie, oral retinoids, methotrexate, cyclosporine, or other immunomodulators) within 4 weeks of baseline.
• Use of Ultraviolet B light (UVB) or oral psoralen with ultraviolet A (PUVA) within 2 weeks of baseline.
• Skin conditions (e.g. eczema) psoriasis that may interfere with evaluations of psoriasis.
• Known hypersensitivity to Sorilux Foam Ointment or any of its components.
• Known hypersensitivity to Olux E Foam or any of its components.
• Contraindications according to the Sorilux Foam or Olux E Foam package inserts.
• Current drug or alcohol abuse (Investigator opinion).
• Subject unable to commit to all the assessments required by the protocol.
• Current enrollment in another clinical study and treatment with another experimental drug or approved therapy for experimental use within 30 days prior to the Screening

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Stiefel, a GSK Company

INDUSTRY

Sponsor Role: collaborator

Leon Kircik, M.D.

OTHER

Sponsor Role: lead

Responsible Party

Leon Kircik, M.D.

Medical Doctor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Leon H Kircik, MD

Role: PRINCIPAL_INVESTIGATOR

DermResearch, PLLC

Locations

DermResearch, PLLC

Louisville, Kentucky, United States

Countries

United States

Other Identifiers

OLX0112

Identifier Type: -

Identifier Source: org_study_id